A carregar...
Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage
BACKGROUND: Intraparenchymal hemorrhage (IPH) is a relative contraindication to bevacizumab therapy, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody approved for the treatment of recurrent glioblastoma. However, in patients with symptomatic enhancing tumors and poor functional...
Na minha lista:
| Publicado no: | Neurooncol Pract |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6479824/ https://ncbi.nlm.nih.gov/pubmed/31044081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npw008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|